Diabetes is often described as a problem of insulin resistance or insulin deficiency.

But inside the insulin-producing beta cell, the story is more detailed.

Researchers have identified a role for tiny cell structures called peroxisomes in beta-cell health.

Peroxisomes help cells break down fats and manage damaging molecules produced during normal metabolism.

That matters because beta cells are unusually sensitive to oxidative stress.

They have to sense glucose, produce insulin and release it at the right time.

If their internal machinery becomes stressed, insulin production can become less reliable.

In animal models, researchers disrupted peroxisome function by targeting a gene needed for normal peroxisome activity.

The result was not simply less insulin.

It was more complicated.

The animals developed glucose intolerance early in life, meaning their bodies struggled to keep blood sugar under control.

Yet their beta cells released more insulin in response to sugar.

That sounds contradictory, but it makes the finding more interesting.

More insulin does not automatically mean better glucose control if the insulin itself is damaged or the beta cell is losing its mature identity.

Researchers found evidence of oxidised insulin proteins.

That means insulin had undergone chemical changes linked to oxidative stress.

They also found reduced markers of mature beta-cell identity.

In plain English, the cells looked less like fully specialised insulin-producing cells.

The study does not prove the same mechanism is driving diabetes in humans.

It is animal research and needs much more work.

But it adds another layer to how we think about diabetes progression.

• Misfolded insulin may be part of how diabetes damages beta cells
• New protective gel could help transplanted insulin-producing cells survive in type 1 diabetes

Beta-cell failure may not just be about the pancreas being overworked.

It may involve damage to the cell’s internal quality-control systems, including structures that manage fat processing and oxidative stress.

If future studies confirm the relevance in people, peroxisome function could become a new research target.

The goal would be to protect beta cells before they fail, rather than simply forcing them to release more insulin.

That is a more ambitious and more interesting direction for diabetes treatment.

Study link: Reduced peroxisomal function increases insulin secretion, promotes insulin oxidation and impairs beta cell maturity

Taking the stairs is not glamorous, but it may be one of the easiest ways to add meaningful movement into everyday life.

A new analysis from the University of East Anglia and the Norfolk and Norwich University Hospital suggests stair climbing is linked with a substantially lower risk of early death.

Researchers reviewed nearly 1,900 studies and analysed nine higher-quality studies involving more than 480,000 people.

The median follow-up period was 14 years, which gives the findings more weight than a short lifestyle snapshot.

People who regularly climbed stairs were 39% less likely to die from cardiovascular disease than those who did not climb stairs often.

They were also 24% less likely to die from any cause.

The same pattern appeared for major cardiovascular conditions.

People who climbed stairs more often were less likely to develop heart attack, stroke and heart failure.

That is important because heart disease remains one of the biggest risks for people living with diabetes.

• More daily steps can lower health risk even for people who sit a lot
• Forget 10,000 steps: for older women, 4,000 is enough

Diabetes already increases the likelihood of cardiovascular disease, so any practical habit that improves heart health is worth taking seriously.

Stair climbing works because it is a short, intense form of activity.

It raises the heart rate quickly, uses large muscles in the legs and challenges the lungs more than flat walking.

It is also built into daily life.

There is no kit, no class and no commute to a gym.

The study also points to a dose question.

One large cohort suggested around six flights of stairs a day may deliver strong benefit, although researchers say the ideal amount still needs more work.

The better message is that even small changes seem to matter.

Choosing stairs at work, in shops or at home can turn wasted moments into useful movement.

For people with type 2 diabetes, this may support fitness, weight management, blood pressure and glucose control over time.

But stair climbing is not for everyone.

Anyone with balance problems, severe joint pain, breathlessness, chest symptoms or foot complications should be cautious and speak to a clinician if unsure.

People with diabetes-related neuropathy should also think carefully about footwear, sensation and fall risk.

The takeaway is simple.

Where it is safe, taking the stairs is a low-cost habit with a surprisingly strong health signal.

It will not replace structured exercise, but it can make an inactive day less inactive.

Arjun Panesar has been featured in Scientists Making a Difference, a science education initiative designed to bring the stories of remarkable scientists into schools and classrooms.

His chapter, Decoding Data, focuses on using data to help people live healthier lives.

It is a fitting theme for someone whose career has been built around turning health data, artificial intelligence and lived experience into practical tools for people with diabetes and other long-term conditions.

Arjun’s story began with family.

After his grandfather was diagnosed with type 2 diabetes, Arjun founded Diabetes.co.uk in 2003 while studying Computing and Artificial Intelligence at Imperial College London.

What started as an online community grew into one of the world’s largest diabetes platforms.

From there, it became the foundation for DDM Health and its evidence-based digital health services.

As Founding CEO and Head of AI and Ethics at DDM Health, Arjun has spent more than two decades working at the intersection of data, prevention, diabetes, obesity and health inequalities.

His work has helped move digital health beyond simple tracking apps and into personalised, clinically meaningful support.

The point is not technology for its own sake.

It is technology that helps people make better decisions, access support earlier and manage health in ways that fit real life.

Arjun’s contribution has been recognised widely.

Imperial College London named him an Emerging Alumni Leader in 2020, recognising alumni under 40 who have shown outstanding achievement, leadership and social impact.

Imperial’s profile highlighted how his work helped more than a million people better manage chronic health conditions, including type 2 diabetes, prediabetes, obesity and fatty liver disease.

DDM Health’s work has also earned major industry recognition.

In 2024, DDM Health and University Hospitals Coventry and Warwickshire NHS Trust won the HSJ Digital Award for Empowering Patients Through Digital for Gro Health W8Buddy.

The platform was recognised for supporting people on specialist weight management pathways and for showing how digital tools can improve access, personalisation and outcomes.

Earlier recognition includes Diabetes Digital Media being named Most Influential Diabetes Technology Company of the Year at the Diabetes Professional Care Industry Awards.

DDM also won an Innovation award at the UK Business Awards, where judges praised the company’s work in changing how type 2 diabetes prevention and management can be delivered.

Arjun is also a bestselling author and recognised thought leader in healthcare AI.

His books include Machine Learning and AI in Healthcare, now in two editions, and Precision Health and Artificial Intelligence.

He has also contributed to Springer’s Handbook of Global Health.

His writing has helped frame some of the central questions facing healthcare AI: how to use data safely, how to avoid bias, how to protect privacy and how to make precision health useful for people who are too often left behind.

His academic roles reflect that same focus.

Arjun is an Honorary Associate Professor at Warwick Medical School, a lecturer at WMG, University of Warwick, an advisor to the University of Sheffield Information School and a mentor at the UCL Institute for Global Health.

Through these roles, he teaches and advises on artificial intelligence, ethics, the digital phenotype and precision health.

• Who is Arjun Panesar
• New study finds weight loss app W8Buddy boosts outcomes in specialist obesity services

That combination of practical delivery, academic contribution and public impact is what makes the Scientists Making a Difference recognition feel well-earned.

Arjun is not being recognised simply for building a company.

He is being recognised for showing how data can be used responsibly to improve health, reduce inequalities and help people live better.

For a UK diabetes audience, the significance is obvious.

Diabetes care is becoming more digital, more personalised and more data-driven.

Arjun’s work has helped shape that shift from the inside.

His inclusion in Scientists Making a Difference gives that story a wider audience: students, teachers and the next generation of scientists who may now see health data and AI as a route to making a real difference.

• Read more at the Scientists Making a Difference website

Taking the stairs is not glamorous, but it may be one of the easiest ways to add meaningful movement into everyday life.

A new analysis from the University of East Anglia and the Norfolk and Norwich University Hospital suggests stair climbing is linked with a substantially lower risk of early death.

Researchers reviewed nearly 1,900 studies and analysed nine higher-quality studies involving more than 480,000 people.

The median follow-up period was 14 years, which gives the findings more weight than a short lifestyle snapshot.

People who regularly climbed stairs were 39% less likely to die from cardiovascular disease than those who did not climb stairs often.

• More daily steps can lower health risk even for people who sit a lot

They were also 24% less likely to die from any cause.

The same pattern appeared for major cardiovascular conditions.

People who climbed stairs more often were less likely to develop heart attack, stroke and heart failure.

That is important because heart disease remains one of the biggest risks for people living with diabetes.

Diabetes already increases the likelihood of cardiovascular disease, so any practical habit that improves heart health is worth taking seriously.

Stair climbing works because it is a short, intense form of activity.

It raises the heart rate quickly, uses large muscles in the legs and challenges the lungs more than flat walking.

It is also built into daily life.

There is no kit, no class and no commute to a gym.

The study also points to a dose question.

One large cohort suggested around six flights of stairs a day may deliver strong benefit, although researchers say the ideal amount still needs more work.

The better message is that even small changes seem to matter.

• Boosting GLP-1: how to increase GLP-1 levels naturally
• Weight loss injection adverts from CheqUp, MedExpress and WLO pulled after regulator steps in
• Forget 10,000 steps: for older women, 4,000 is enough

Choosing stairs at work, in shops or at home can turn wasted moments into useful movement.

For people with type 2 diabetes, this may support fitness, weight management, blood pressure and glucose control over time.

But stair climbing is not for everyone.

Anyone with balance problems, severe joint pain, breathlessness, chest symptoms or foot complications should be cautious and speak to a clinician if unsure.

People with diabetes-related neuropathy should also think carefully about footwear, sensation and fall risk.

The takeaway is simple.

Where it is safe, taking the stairs is a low-cost habit with a surprisingly strong health signal.

It will not replace structured exercise, but it can make an inactive day less inactive.

Cured meats are often discussed as if the whole problem is nitrates.

That is too simple.

The cancer risk linked to processed meat appears to come from a combination of factors: nitrites, heme iron, smoking, charring, salt, processing methods and the overall food matrix.

Processed meat includes meat preserved by curing, salting, smoking, fermentation or similar methods.

That means foods such as bacon, ham, salami, sausages, chorizo and some deli meats.

In 2015, the International Agency for Research on Cancer classified processed meat as carcinogenic to humans.

• Proccessed and ultra-processed foods: how do they affect your health?

The strongest evidence is for colorectal cancer.

That classification does not mean processed meat carries the same level of risk as every other Group 1 carcinogen.

It means there is strong evidence of a cancer hazard.

The chemistry is important.

Nitrates and nitrites can be transformed in the body into reactive compounds.

Under certain conditions, these can form N-nitroso compounds, some of which can damage DNA.

Heme iron from red meat may also promote formation of these compounds in the gut.

High-temperature cooking adds another layer.

Pan-frying, grilling, smoking and direct flame exposure can create substances such as heterocyclic aromatic amines and polycyclic aromatic hydrocarbons.

These compounds are also linked with DNA damage.

That is why the source and preparation method matter.

A vegetable rich in nitrate is not the same as cured bacon.

Nitrate and nitrite ions may be chemically identical, but the surrounding food matrix changes what happens next.

Vegetables bring fibre, polyphenols and vitamins such as vitamin C and E, which can reduce nitrosation and steer chemistry towards nitric oxide rather than harmful N-nitroso compounds.

This is why plant-derived nitrate has not shown the same cancer-risk pattern as processed meat in current evidence.

The “natural” label can also mislead.

Some meats cured with nitrate-rich vegetable extracts may still generate nitrite during processing.

So “no added synthetic nitrite” does not necessarily mean nitrite-free or risk-free.

For people with diabetes, processed meats also raise another issue.

They are often high in salt and may be part of dietary patterns linked with poorer cardiovascular health.

That matters because diabetes already raises heart and stroke risk.

• Ultra-processed foods may affect focus even in people with healthy diets
• Ultra processed foods may raise asthma risk in children
• Ultra-processed food intake linked to poorer thigh muscle quality

The most sensible advice is not panic.

It is moderation.

Processed meat should not be an everyday staple.

Fresh poultry, fish, eggs, pulses, tofu, nuts and minimally processed meats are better regular protein options.

Cooking methods matter too.

Avoid charring, reduce direct-flame cooking and pair meals with fibre-rich foods such as vegetables, beans, lentils and wholegrains.

This is not about demonising one food.

It is about recognising that processing changes biology, and some processed meats carry risks that cannot be explained away by calling them traditional, natural or high protein.

Ultra-processed foods are no longer just a weight story.

A new study has linked higher intake of ultra-processed foods with a greater risk of prostate cancer in men.

Researchers analysed data from 17,024 US men who took part in the National Health and Nutrition Examination Survey between 2003 and 2023.

They used dietary recalls to estimate how much of each person’s daily energy intake came from ultra-processed foods.

These include products such as soft drinks, packaged cereals, processed snacks, processed meats and many ready-made foods.

They are usually manufactured with refined starches, oils, sugars, salt and additives designed to improve texture, flavour and shelf life.

• Ultra-processed foods may affect focus even in people with healthy diets
• Ultra processed foods may raise asthma risk in children
• Ultra-processed food intake linked to poorer thigh muscle quality

The men were divided into four groups, from less than about 20% of calories from ultra-processed foods to more than 44%.

Compared with men in the lowest group, those in the higher-consumption groups had a higher risk of prostate cancer.

The three higher-consumption groups had a 29% greater risk.

The two highest-consumption groups had a 30% greater risk.

After adjusting for age, race and ethnicity, smoking and poverty status, the increased risk remained significant, ranging from 24% to 31%.

The highest-intake group alone showed a possible 34% higher risk, although that result did not reach statistical significance.

That may reflect the smaller number of prostate cancer cases in that subgroup.

The study is observational, so it cannot prove ultra-processed foods directly caused prostate cancer.

Diet data can also be imperfect, and people who eat more ultra-processed foods may differ in many other ways.

Still, the result fits a broader pattern.

Ultra-processed diets have been linked with obesity, poor metabolic health, cardiovascular disease, inflammation and early death.

Researchers think several mechanisms could be involved in cancer risk.

These include metabolic disruption, oxidative stress, chronic inflammation and changes in the gut microbiome.

• Microwave-assisted frying could make chips less oily
• Gut microbes may affect how many calories you absorb from food
• Gut microbiome may shape how diet influences cancer growth and immune defence

For a diabetes audience, the overlap is hard to ignore.

The same foods that make glucose control, weight management and blood pressure harder may also be part of a wider cancer-risk picture.

That does not mean every packaged food is dangerous.

But it does mean a diet built around soft drinks, processed meats, crisps, sweet cereals and ready-made snacks is not neutral.

The practical move is not perfection.

It is replacing the most frequent ultra-processed foods with simpler staples more often: whole grains, pulses, vegetables, fruit, eggs, fish, yoghurt, nuts and minimally processed proteins.

In prostate cancer prevention, as in diabetes care, the boring foundations still matter.

The brain is not only thinking, remembering and controlling the body.

It is also cleaning up after itself.

The glymphatic system helps clear waste products from the brain, especially during sleep.

When that system works poorly, damaging proteins and metabolic debris may build up.

That is one reason researchers are increasingly interested in how glymphatic function relates to dementia and cognitive decline.

A new review from Victoria University suggests exercise may be one way to support this clean-up process.

The evidence is not yet complete, but the biological logic is strong.

• Exercise may help the ageing brain clear waste
• How to exercise safely when the weather is hot

Exercise improves vascular function.

That matters because glymphatic clearance depends partly on healthy fluid movement and blood vessel dynamics.

Exercise can also reduce blood pressure, lower vascular stiffness and improve blood flow.

It can calm inflammation in the brain and alter norepinephrine, a chemical involved in arousal and stress.

Sleep may be the key link.

The glymphatic system is especially active during deep sleep, and regular exercise is one of the more reliable ways to improve sleep quality.

This is important because sleep often becomes harder with age, just as the brain’s need for repair and clean-up becomes more urgent.

For people with diabetes, the message is especially relevant.

Diabetes is linked with vascular disease, inflammation, sleep problems and higher dementia risk.

Exercise hits all of those pathways at once.

• Boosting GLP-1: how to increase GLP-1 levels naturally
• Forget 10,000 steps: for older women, 4,000 is enough

It improves insulin sensitivity, helps blood pressure, supports sleep and may now also help brain waste clearance.

The researchers still need to identify the best exercise type, dose and timing.

It may turn out that aerobic exercise, resistance training or a combination has different effects.

But this does not need to wait for the perfect trial before becoming useful.

Regular movement remains one of the most powerful tools for healthy ageing.

It may help your brain not by doing one dramatic thing, but by quietly improving the conditions it needs to maintain itself.

Meditation is often sold in watered-down language: relax, breathe, clear your mind.

A new study suggests intensive practice may do more than that, although the findings need careful handling.

Researchers studied 20 healthy adults taking part in a seven-day residential retreat.

The programme included lectures, around 33 hours of guided meditation and group healing practices.

Some elements used an open-label placebo approach, where participants knew there was no active medical ingredient involved.

Before and after the retreat, researchers measured brain activity using fMRI and analysed blood samples for biological changes.

They reported changes across several systems.

Brain regions linked with internal mental chatter showed less activity during meditation.

The researchers interpreted this as a sign of more efficient brain function.

• Mediterranean-style eating linked to lower stroke risk in women
• High intensity yoga shows strongest link for better sleep

There were also signs of increased neuroplasticity.

In laboratory experiments, neurons exposed to participants’ post-retreat blood plasma grew longer branches and formed more connections.

That suggests something in the blood environment had shifted in a way that supported neuronal growth in the lab.

The study also found changes in metabolism.

Cells exposed to post-retreat plasma showed increased glycolytic activity, meaning greater sugar-burning metabolism.

Immune signalling changed too, with both inflammatory and anti-inflammatory signals rising.

That suggests an adaptive immune response rather than a simple “inflammation went down” story.

Endogenous opioids also increased.

These are the body’s own pain-regulating chemicals, acting on some of the same systems targeted by opioid medicines.

This may be relevant to future pain research.

The researchers also looked at subjective experience.

Participants reported stronger mystical-type experiences after the retreat, and those experiences were linked with greater integration across brain networks.

Some patterns resembled brain connectivity findings from psychedelic research.

That does not mean meditation and psychedelics are the same.

• Yoga and meditation may influence gut bacteria
• Mediterranean diet may boost mitochondrial signals linked to heart and brain health

It means different routes may sometimes engage overlapping neural patterns linked with altered states of consciousness.

The caveats are important.

The study was small, involved healthy adults and combined several interventions at once.

It cannot say which part of the retreat caused which change.

One co-author was also linked to the company offering the retreat.

So the study should not be treated as proof that a meditation retreat cures pain, depression, diabetes or any other condition.

But it does support a serious idea.

Attention, belief, social context and repeated mental practice can leave measurable biological fingerprints.

That is worth studying properly.

Alcohol research is messy because drinking is never just about alcohol.

It is also about lifestyle, meals, income, culture, drinking patterns and health status.

A large UK Biobank analysis tried to look more closely at those differences by separating wine from beer, cider and spirits.

The study included more than 340,000 adults and followed them for more than 13 years on average.

The clearest finding was not surprising.

Heavy drinking was linked with worse outcomes, regardless of what people drank.

Compared with never or occasional drinkers, high-consumption drinkers were more likely to die from any cause.

They also had higher risks of death from cancer and heart disease.

At lower levels of drinking, the pattern differed by drink type.

Wine consumption was associated with lower risk in some outcomes.

Moderate wine drinkers had a 21% lower risk of cardiovascular death compared with never or occasional drinkers.

By contrast, even low levels of spirits, beer or cider were linked with a higher risk of cardiovascular death.

There are plausible explanations.

Wine, especially red wine, contains polyphenols and other compounds that may have cardiovascular effects.

But lifestyle may matter even more.

Wine is more often consumed with meals and is often linked with healthier overall diet and socioeconomic patterns.

Beer, cider and spirits may be more likely to be consumed outside meals or alongside less healthy behaviours.

The researchers adjusted for many factors, but adjustment never removes every difference.

That is why the results should not be turned into advice to start drinking wine.

For people with diabetes, alcohol needs particular caution.

• Moderate wine intake linked to slower biological ageing in men
• High intake of white wine associated with increased risk of skin cancer – but not red wine
• Beer contains vitamin B6 but may not be the most sensible way to get it

It can affect blood glucose, increase hypo risk for people on insulin or sulfonylureas, add calories and worsen sleep.

Some drinks are also high in carbohydrate or consumed with salty, fatty foods.

The safest interpretation is narrow.

Heavy drinking is harmful.

Drink type and drinking pattern may influence risk.

But alcohol is not a health treatment, and wine is not a substitute for the basics: not smoking, healthy weight, blood pressure control, movement, sleep and good diabetes management.

For decades, people were told to choose low-fat dairy.

The logic was simple: dairy contains saturated fat, saturated fat can raise cholesterol, so lower-fat dairy must be healthier.

A new Canadian study suggests the real picture is less tidy.

Researchers studied 74 adults with overweight or obesity over 12 weeks.

Some followed a low-dairy calorie-restricted diet.

Others consumed three servings of full-fat dairy each day, either as part of an energy-neutral diet or an unrestricted diet.

The results did not show the harms many people would expect.

Three daily servings of full-fat dairy did not meaningfully worsen body weight, body composition, cholesterol, blood lipids or insulin resistance.

People in the higher-dairy groups also consumed more calcium, protein and vitamin D.

They showed improvements in blood pressure too.

The explanation may lie in what nutrition researchers call the dairy matrix.

Food is not just a bundle of separate nutrients.

Dairy contains casein, whey, fat, minerals and other compounds held together in a physical structure.

That structure may affect how nutrients are digested, absorbed and used.

In other words, the effect of full-fat yoghurt or milk may not be predicted simply by looking at saturated fat on a label.

That does not mean everyone should start eating unlimited cheese.

Portion size still matters.

• Fat tissue blood vessels may play a bigger role in obesity and type 2 diabetes than previously thought
• Ozempic face: weight loss jabs can lead to muscle loss as well as fat loss
• Belly fat plus low muscle mass linked to higher death risk

So does the type of dairy, the rest of the diet and individual health needs.

For people with diabetes, unsweetened yoghurt, milk and some cheeses can be useful sources of protein and calcium.

The bigger issue is often added sugar in flavoured yoghurts and dairy desserts, not the presence of dairy fat alone.

The study was also small and relatively short.

It does not overturn all dietary guidance.

But it does challenge a lazy assumption.

Low-fat is not automatically better, and full-fat is not automatically harmful.

As usual, the whole food and the whole diet matter more than one nutrient in isolation.

Researchers are investigating whether a short voice recording could one day help health services identify people at greater risk of heart and circulation problems.

DDM Health and Royal Holloway, University of London have received Innovate UK funding as part of the Biomedical Catalyst for the 24-month project.

The researchers will study whether features within a person’s speech, when considered alongside existing health information, can provide useful warning signals relating to high blood pressure, unhealthy cholesterol levels, heart failure and stroke risk.

The £540,161 project will focus on adults living with obesity or type 2 diabetes, who are more likely to develop heart and circulation conditions.

These problems can progress without obvious symptoms, meaning opportunities for earlier support may be missed.

The research will explore whether a short recording made using a smartphone or connected device could provide an additional, convenient way to flag people who may benefit from further assessment.

Arjun Panesar, Founding CEO and Head of Ethical AI at DDM Health, said: “Many heart and circulation risks develop quietly, particularly among people already living with obesity or type 2 diabetes.

“A short voice recording is familiar, remote and non-invasive. We want to find out whether it can provide an additional useful signal that helps identify people who may benefit from earlier assessment and support.

“This is not about diagnosing somebody from their voice or replacing doctors. It is about researching whether voice can add useful information to support clinical decisions.

“We now have the opportunity to develop the technology responsibly, test it rigorously and understand both its potential and its limitations.”

• Study to detect type 2 diabetes from voice launches

DDM Health and Royal Holloway will develop a research prototype and examine its performance and usability.

The technology is at the research stage and is not currently available to patients.

It will not diagnose medical conditions on its own, and any future use would depend on the results of the research and the relevant clinical, regulatory and safety requirements.

The project will run until 31 May 2028.

Many people use cannabis to relax.

A new study suggests the relationship with stress may be more complicated than that.

Researchers at Oregon State University looked at frequent cannabis use and cortisol, the hormone often described as the body’s stress hormone.

Cortisol is not bad in itself.

It helps regulate blood pressure, blood glucose, inflammation and the body’s response to pressure.

Levels normally rise after waking, helping prepare the body for the day.

This is known as the cortisol awakening response.

In the study, frequent cannabis users did not show a bigger morning rise than non-users.

The more interesting finding was that their cortisol was already higher when they woke up.

That suggests their daily stress rhythm may be altered before the day has even started.

The study cannot prove cannabis caused this.

It also cannot prove higher cortisol makes people use cannabis more often.

The researchers are clear that longer-term studies are needed to untangle cause and effect.

Still, the finding is worth taking seriously.

Stress is one of the most common reasons people report using cannabis.

If frequent use ends up disrupting the stress system, a difficult loop could develop.

Someone uses cannabis to manage stress, but their biological stress rhythm becomes less stable, which may increase the urge to use again.

For people with diabetes, cortisol is not a side issue.

• Cannabis use was linked to higher testosterone in young men
• Gut condition seen to be why cannabis users are ending up in A&E

It can affect blood glucose, appetite, sleep and blood pressure.

That does not mean every cannabis user will see a clear glucose effect, but it does mean the stress-hormone angle matters.

Cannabis is often discussed as if the only question is whether it is legal or illegal.

Health is more nuanced than that.

Regular use may have effects on sleep, mental health, motivation, appetite and now possibly stress biology.

The study is not a moral panic.

It is a warning that “stress relief” can come with biological trade-offs.

Many people know their cholesterol number.

Far fewer know their Lp(a).

That could matter because lipoprotein(a), often shortened to Lp(a), is an inherited cholesterol-related particle that can raise cardiovascular risk even when standard cholesterol results look acceptable.

A large analysis of more than 20,000 people found that very high Lp(a) levels were independently linked with greater risk of major cardiovascular events.

The researchers looked at participants from three major NIH trials: ACCORD, PEACE and SPRINT.

They measured Lp(a) in stored blood samples and followed cardiovascular outcomes.

An Lp(a) level of 175 nmol/L or above was associated with a higher risk of major cardiovascular events.

• Eye clinics could help catch dangerous blood pressure in people with diabetes
• Retatrutide improves blood sugar and weight loss in type 2 diabetes trial

It was also linked with higher risk of cardiovascular death and stroke.

Interestingly, it was not linked with a higher risk of heart attack in this analysis.

The association appeared stronger in people who already had heart disease than in those without existing disease.

This is clinically important because high Lp(a) is mostly genetic.

Lifestyle changes do not usually lower it dramatically.

But knowing someone has high Lp(a) can still change management.

It may justify more aggressive control of other modifiable risk factors such as LDL cholesterol, blood pressure, smoking, weight, glucose and kidney health.

For people with diabetes, the relevance is obvious.

Diabetes already increases cardiovascular risk.

• Delivered groceries improved blood sugar in people with type 2 diabetes
• Higher blood sugar linked to faster brain ageing

If someone also has high Lp(a), the hidden inherited risk may add another layer.

A standard lipid panel may not pick this up.

Lp(a) needs its own blood test.

The study does not mean everyone with high Lp(a) is destined to have a stroke or heart disease.

It means risk may be underestimated if Lp(a) is never measured.

New targeted treatments are also being developed, which makes identifying high-risk patients more useful.

For now, the practical message is simple.

If you have diabetes, early heart disease in the family or unexplained cardiovascular risk despite decent cholesterol numbers, it may be worth asking your clinician whether Lp(a) testing is appropriate.

Fruit juice has a complicated reputation.

It can help people increase fruit intake, but it can also deliver sugar quickly and without the fibre of whole fruit.

A small Newcastle University trial adds another layer to the debate.

Researchers recruited 42 adults who were eating two or fewer portions of fruit and vegetables a day.

Some were supported to reach 5-a-day using whole fruits and vegetables only.

• Frozen fruit and canned vegetables can be just as useful as fresh food
• Fruit, coffee, chocolate and wine may reduce risk of metabolic syndrome by 23%

Others were supported to increase whole fruit and vegetables while also adding one daily glass of 100% fruit juice or a smoothie.

After four weeks, both intervention groups had increased their fruit and vegetable intake.

Both also increased fibre intake by around 8 to 10g per day.

But the group including juice or smoothies had lower depression scores than the control group.

The difference was modest but statistically significant.

That is interesting, especially because diet and mental wellbeing are increasingly being linked in research.

Fruit and vegetables provide polyphenols, vitamins, minerals and other compounds that may influence inflammation, blood flow and brain function.

Citrus juices in particular have been studied for possible effects on brain blood flow and cognition.

But this is not a free pass to drink large amounts of juice.

The study was small, lasted only four weeks and was funded by the Fruit Juice Science Centre.

It also did not focus on people with diabetes.

That matters because fruit juice can raise blood glucose rapidly.

For someone with type 2 diabetes, prediabetes or insulin resistance, whole fruit is usually a better option because it comes with fibre and tends to be more filling.

If juice is used, it should be a small glass and counted as part of total carbohydrate intake.

• Gut may help the brain decide which meals are worth remembering
• Oral GLP-1 drugs may turn down the brain’s food craving circuit
• Ozempic breath: gum and mint sales may be getting a boost from GLP-1 users

The useful message is broader.

Helping people reach 5-a-day may need practical, affordable options.

Not everyone can regularly buy and prepare fresh produce.

A small glass of 100% juice or a smoothie may help some people move in the right direction, especially if it does not replace whole fruit and vegetables.

For diabetes, the priority remains balance.

Mood matters, fruit intake matters and blood glucose matters too.

Health is not only shaped by food, exercise and blood pressure.

A new study suggests social experience may also leave a biological mark on ageing.

Researchers analysed data from 1,309 adults taking part in the Midlife in the United States study.

Participants completed clinic visits that included blood and urine samples, physical assessments and measures of stress-related biology.

They were then followed for nearly 15 years on average.

During that period, 150 participants died.

The researchers looked at positive social experiences such as marriage, parenting, volunteering, attending group meetings and helping others without pay.

They also examined negative experiences, including stressful life events, childhood adversity and adult adversity.

To understand the biology, they used epigenetic ageing measures.

• Filtered coffee linked to slower biological ageing, while instant coffee showed the opposite

These included GrimAge2, PhenoAge and DunedinPACE, which estimate biological ageing from patterns of DNA methylation.

They also measured allostatic load, which is the cumulative wear and tear placed on the body by repeated stress.

Positive social experiences were linked with slower epigenetic ageing and lower allostatic load.

Marriage and attending meetings were associated with slower ageing on some measures.

Positive social experience was also linked with longer survival.

By contrast, childhood adversity predicted shorter survival and faster biological ageing.

Some specific early-life adversities, such as dropping out of school, were linked with higher mortality risk.

Parental drug problems were linked with faster GrimAge2 ageing and greater allostatic load.

Adult adversity was associated with inflammation and metabolic disruption, including glucose-related dysregulation.

However, after adjustment, adult negative experiences were not independently linked with mortality in the same way as childhood adversity.

The strongest biological pathway appeared to be epigenetic ageing, especially GrimAge2.

That measure partly explained the link between social experience and mortality.

Inflammation played a smaller role.

This does not prove that getting married, joining a club or volunteering will directly extend life.

People with richer social lives may differ in health, income, education and opportunity.

The sample was also healthier and more advantaged than the wider population.

• Social media has negative impact on pre-teens cognitive performance
• Staying social in later life may protect against dementia
• Social media influencers raking in thousands for promoting weight loss jabs

Even so, the study makes an important point.

Loneliness, early adversity and social disconnection are not just emotional experiences.

They may be tied to stress biology, inflammation and ageing systems.

For people with diabetes, this matters.

Social support can affect food choices, medication routines, physical activity, mood and the ability to keep going with long-term self-management.

The message is not that relationships replace medical care.

It is that connection belongs in the health conversation.

A life with support, purpose and belonging may help the body carry less biological strain.

Ageing is the biggest known risk factor for dementia, but the reason is still not fully understood.

A new NIH-funded study points to one possible mechanism: the brain’s immune environment may change sharply in midlife.

Researchers studied post-mortem hippocampal tissue from 40 neurologically healthy adults aged 20 to 95.

The hippocampus is central to memory and learning, and it is one of the brain regions most relevant to Alzheimer’s disease.

The team used advanced single-cell techniques to look at the identity and behaviour of cells in exceptional detail.

They found that microglia, the brain’s main resident immune cells, gradually decline from around age 50 to 75.

• Gut may help the brain decide which meals are worth remembering
• Oral GLP-1 drugs may turn down the brain’s food craving circuit

At the same time, the brain appears to gain cells with stronger inflammatory signals and features more like immune cells from the blood.

That is a big deal because microglia have long been thought of as cells that develop early in life and renew themselves within the brain.

This study suggests the ageing hippocampus may be more dynamic, and potentially more vulnerable, than that model allowed.

The researchers also found signs of age-related decline in cells involved in maintaining the blood-brain barrier.

That barrier helps control what passes from the bloodstream into the brain.

If it weakens, inflammation and vascular damage may become more likely.

The study does not prove that this immune shift causes Alzheimer’s or dementia.

But it gives researchers a more precise place to look.

The ageing brain may not simply wear down.

• Heavy TV watching in midlife linked to smaller brain structures later
• CBD improved memory and reduced brain damage in a mouse model of Alzheimer’s disease

It may also change its immune identity in ways that make chronic inflammation more likely.

For people with diabetes, the finding fits a wider pattern.

Metabolic disease, vascular health, inflammation and cognitive decline are tightly connected.

Protecting the brain means thinking beyond memory games.

Blood pressure, glucose, sleep, movement and inflammation all matter.

If future work confirms this immune shift is involved in dementia risk, it could open up new ways to protect the brain before symptoms begin.

A new oral GLP-1 medicine has shown strong weight loss results in a phase 2 trial.

The drug, called aleniglipron, is being developed as a once-daily tablet for people with obesity or overweight.

After 36 weeks, people taking the highest dose lost an average of 12.1% of their body weight.

That compares with just 0.5% in the placebo group.

Lower doses also led to meaningful weight loss, with average reductions of 9.0% and 10.7%.

The trial included 230 adults across 38 medical centres in the United States.

• GLP-1 weight loss drugs may be misused by people with eating disorders
• First GLP-1 pill for weight loss approved in the UK

Participants were randomly assigned to receive either placebo or aleniglipron at doses of 45mg, 90mg or 120mg.

The dose was increased every four weeks during treatment.

The drug works through the GLP-1 pathway, the same broad hormone system targeted by medicines such as semaglutide.

GLP-1 medicines help stimulate insulin release, reduce appetite and increase fullness.

That combination can support weight loss and improve blood glucose control.

What makes aleniglipron different is its structure.

Current GLP-1 drugs such as Wegovy and Ozempic are peptide-based medicines, usually given by injection.

Aleniglipron is a small molecule.

That means it is chemically made, taken by mouth and potentially easier to manufacture at scale.

It can also be taken with or without food, which could make it easier to use than some oral medicines that require careful timing around meals.

Side effects were mainly gastrointestinal, as expected with this drug class.

Most were mild to moderate and became less common as the study went on.

Around 10% of participants stopped treatment, and researchers reported no cases of drug-induced liver injury.

That is reassuring, but this is still early.

• Oral GLP-1 drugs may turn down the brain’s food craving circuit
• UK heatwave: people taking GLP-1 weight loss drugs warned to watch for dehydration

Phase 2 trials are designed to explore dose, safety and signal of effect.

They are not the final test.

The real question is whether aleniglipron can perform well in larger, longer phase 3 trials and whether people can stay on it in real-world use.

For people with obesity, type 2 diabetes or both, oral GLP-1 medicines could become important.

They may reduce barriers linked to injections, storage and supply.

But convenience will not be enough on its own.

The drug still needs to prove long-term safety, durability and meaningful health benefit beyond weight loss.

Exercise is usually discussed in terms of the heart, muscles, weight and blood sugar.

But it may also help the brain do one of its least glamorous but most important jobs: clearing out waste.

Researchers at Victoria University reviewed evidence on the glymphatic system, a network involved in removing waste products from the brain.

This clean-up process is especially active during sleep.

That matters because waste build-up in the brain is linked with ageing, inflammation and neurodegenerative disease.

The review suggests exercise may support this system through several routes.

Physical activity can reduce blood pressure and vascular stiffness, both of which matter for healthy blood flow in the brain.

It can also reduce inflammation, improve neuron activity and support better sleep quality.

Deep sleep may be particularly important because slow wave activity is thought to help drive waste clearance.

That creates an interesting chain.

Exercise improves sleep and vascular health.

Better sleep and healthier blood vessels may support the glymphatic system.

A better-functioning glymphatic system may help the brain clear the debris that accumulates with age.

The researchers are not claiming to have found the perfect exercise prescription yet.

They still need to work out which type of exercise matters most, how much is needed and whether the advice should change for people already living with cognitive impairment.

But the basic idea is compelling.

Exercise may protect the brain not only by improving blood sugar, blood pressure and heart health, but by helping it maintain its own housekeeping system.

For people with diabetes, this is especially relevant.

• Gut may help the brain decide which meals are worth remembering
• Oral GLP-1 drugs may turn down the brain’s food craving circuit

Type 2 diabetes is already linked with higher risk of cognitive decline and dementia, partly through effects on blood vessels, inflammation and metabolism.

That makes movement a brain-health intervention as well as a glucose and weight intervention.

The practical message is not complicated.

Walking, cycling, swimming, resistance training or any activity that raises the heart rate may all help.

The best exercise is still the one you can keep doing.

But if you needed one more reason to move, this is it: your brain may need the workout as much as your body does.

The gut and brain are constantly talking.

A new rat study suggests one of their conversations may be about memory.

Researchers at the University of Southern California studied how the body remembers food-related experiences, such as where food was found.

They focused on the vagus nerve, one of the main communication routes between the digestive system and the brain.

When rats ate nutrient-rich foods, neurons connected to the hippocampus released more acetylcholine.

• Tiny particles from the gut may help drive ageing-related disease
• Gut microbiome disruption may influence autism

The hippocampus is central to learning and memory.

Acetylcholine helps the brain record new information.

When researchers disrupted vagus nerve signalling, this acetylcholine rise disappeared.

The rats also performed worse on tasks that required them to remember where they had recently found food.

The interesting part is that the signal was driven by nutritional value, not just taste.

Sweet-tasting low-calorie liquids did not trigger the same memory response.

Sugar or fat did.

The theory is that this system evolved to help animals remember where valuable food sources are.

If a meal provides useful energy or nutrients, the gut sends a message to the brain: remember this.

That makes sense in the wild.

But in modern food environments, it may become a problem.

The same study found that rats exposed to high-fat and high-sugar diets early in life later had weaker communication between the gut and hippocampus.

Even after returning to a healthier diet, their memory-related brain responses remained reduced.

They also performed worse on food-location memory tasks.

• Gut microbes may affect how many calories you absorb from food
• Low Carb Diet: Beginner’s Guide
• Fruit and Diabetes – Can I Eat Fruit?

For people with type 2 diabetes or obesity, this is only animal research, so it should not be overstated.

But it fits with a broader pattern.

Poor diet and metabolic disease are linked with higher risk of cognitive decline, and the gut-brain axis may be one of the reasons.

The study also highlights why ultra-processed foods can be so disruptive.

They may trigger strong reward and memory signals in the short term, but repeated exposure could damage the very systems that help regulate food learning and brain health.

The gut is not just digesting food.

It may also be helping decide what the brain remembers about it.

GLP-1 drugs are best known for reducing appetite and supporting blood glucose control.

New research suggests some oral GLP-1 drugs may also affect the reward side of eating.

That matters because hunger and craving are not the same thing.

A person may not be physically hungry and still feel pulled towards high-reward foods.

Researchers studied small-molecule GLP-1 receptor agonists in mice, including orforglipron and danuglipron.

• First GLP-1 pill for weight loss approved in the UK
• Retatrutide improves blood sugar and weight loss in type 2 diabetes trial
• Retatrutide: How it Works, Evidence, Side Effects

These drugs differ from larger peptide medicines such as semaglutide.

Because they are small molecules, they may enter the brain and act in ways that are not identical to injectable GLP-1 drugs.

In the study, the oral GLP-1 drugs reduced hedonic feeding, meaning eating for pleasure rather than energy need.

The researchers found activity in the central amygdala, a deep brain region involved in desire and reward.

That was unexpected, because previous GLP-1 research has focused more on appetite circuits in the hypothalamus and hindbrain.

Further experiments suggested the drugs reduced dopamine release in parts of the reward system while the mice were eating for pleasure.

In plain English, the drugs seemed to make highly rewarding food less rewarding.

This could be important for obesity and type 2 diabetes, where cravings, food environment and reward-driven eating often make change difficult.

It may also help explain why some people on GLP-1 medicines report reduced interest in alcohol, smoking or other rewards.

But this is still mouse research.

• GLP-1 weight loss drugs may be misused by people with eating disorders
• GLP-1 drugs may change addiction by acting on the brain’s reward system
• Boosting GLP-1: how to increase GLP-1 levels naturally

It does not prove that oral GLP-1 drugs will treat addiction or reliably remove cravings in people.

It also does not mean appetite is purely a brain-reward problem.

Food behaviour is shaped by biology, habit, stress, sleep, money, culture and availability.

Still, the study adds depth to the GLP-1 story.

These medicines may not only reduce hunger.

They may also alter how the brain values food.